Alumis Engages in Upcoming Investor Conferences
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma leader, is set to participate in a series of investor conferences that highlight its innovative approach towards developing groundbreaking therapies for patients with immune-mediated diseases. As the company continues to push the boundaries of biopharmaceutical advancements, these events serve as a platform for Alumis to showcase its latest developments and engage with investors.
Conference Participation Overview
The forthcoming conferences where Alumis will be represented include:
Cantor Global Healthcare Conference 2025
This event will take place in New York City on September 3 at 9:45 am ET. During this conference, a fireside chat is scheduled, providing insight into Alumis's strategic plans and the innovative therapies in its pipeline.
Wells Fargo 2025 Healthcare Conference
On September 5 at 9:30 am ET, Alumis will join the Wells Fargo Healthcare Conference in Boston. This session will further delve into how Alumis aims to revolutionize the treatment landscape for patients living with immune-mediated conditions.
Morgan Stanley Annual Global Healthcare Conference
On September 8 at 4:50 pm ET, Alumis will participate in the renowned Morgan Stanley conference in New York City. The audience will have an opportunity to learn more about Alumis's leading-edge research and development initiatives.
H.C. Wainwright Annual Global Investment Conference
This conference is scheduled for September 9 at 10:30 am ET in New York. Here, Alumis will present its innovative solutions in an insightful presentation designed to capture investor interest.
Baird 2025 Global Healthcare Conference
On September 10 at 2:35 pm ET, the event will further spotlight Alumis’s contributions to the healthcare sector, setting the stage for discussions on the company's future ventures and potential.
Stifel 2025 Virtual Immunology & Inflammation Forum
The final appearance in this series of conferences will be a virtual presentation at the Stifel Forum on September 16 at 12:30 pm ET, emphasizing Alumis’s commitment to advancing treatments in immunology and inflammation.
Accessing Conference Information
For those interested in tuning in, live webcasts for these conferences can be accessed via the “Events” page located in the “Investors” section of the Alumis website. Archived webcasts will be available for review, ensuring that insights from these events can be revisited over the following 90 days.
About Alumis
Alumis is pioneering the development of next-generation therapies targeting immune-mediated diseases, aiming to enhance health outcomes for a range of conditions. With a strong focus on precision medicine and leveraging proprietary data analytics, Alumis is developing novel oral tyrosine kinase 2 inhibitors, including envudeucitinib for conditions like moderate-to-severe plaque psoriasis and systemic lupus erythematosus, alongside A-005 targeting neuroinflammatory and neurodegenerative diseases. The company is also working on lonigutamab, which targets thyroid eye disease and has several promising preclinical programs.
Frequently Asked Questions
What is Alumis known for?
Alumis is recognized for its advancements in targeted therapies for immune-mediated diseases, focusing on innovative treatment options.
When will Alumis participate in the Cantor Global Healthcare Conference?
The conference will take place on September 3 at 9:45 am ET.
How can investors access live webcasts of these events?
Live webcasts can be accessed through the “Events” page in the “Investors” section of the Alumis website.
What types of therapies is Alumis developing?
Alumis is developing a pipeline of oral tyrosine kinase inhibitors and targeted therapies for various immune-mediated diseases.
Is there a virtual component to Alumis's conference participation?
Yes, Alumis will have a virtual presentation at the Stifel 2025 Virtual Immunology & Inflammation Forum on September 16 at 12:30 pm ET.
